Modeling the acute mucosal toxicity to fractionated radiotherapy combined with the ATM inhibitor WSD0628.

Autor: Garcia DA; Mayo Clinic, Rochester, Minnesota, United States., Rathi S; University of Minnesota, Minneapolis, MN, United States., Connors MA; Mayo Clinic, Rochester, Minnesota, United States., Grams M; Mayo Clinic, Rochester, United States., Vaubel RA; Mayo Clinic, Rochester, MN, United States., Bakken KK; Mayo Clinic, Rochester, MN, United States., Ott LL; Mayo Clinic, Rochester, Minnesota, United States., Carlson BL; Mayo Clinic, Rochester, United States., Hu Z; Mayo Clinic, Rochester, MN, United States., Decker PA; Mayo Clinic, Rochester, United States., Eckel-Passow JE; Mayo Clinic, Rochester, MN, United States., Burgenske DM; Mayo Clinic, Rochester, MN, United States., Zhong W; Wayshine Biopharm, United States., Trzasko JD; Mayo Clinic, United States., Herman MG; Mayo Clinic, Rochester, MN, United States., Elmquist WF; University of Minnesota, Minneapolis, MN, United States., Remmes NB; Mayo Clinic, Rochester, MN, United States., Sarkaria JN; Mayo Clinic, Rochester, MN, United States.

Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.

Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors.

Autor: Rathi S; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.) elmq011@umn.edu rathi029@umn.edu., Mladek AC; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Oh JH; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Dragojevic S; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Burgenske DM; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Zhang W; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Talele S; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Zhang W; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Bakken KK; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Carlson BL; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Connors MA; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., He L; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Hu Z; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Sarkaria JN; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.)., Elmquist WF; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota (S.R., J.-H.O., W.J.Z., S.T., W.Q.Z., W.F.E.) and Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota (A.C.M., S.D., D.M.B., K.K.B., B.L.C., M.A.C., L.H., Z.H., J.N.S.) elmq011@umn.edu rathi029@umn.edu.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2024 Oct 18; Vol. 391 (2), pp. 346-360. Date of Electronic Publication: 2024 Oct 18.

ATM inhibition exploits checkpoint defects and ATM-dependent double strand break repair in TP53-mutant glioblastoma.

Autor: Laverty DJ; Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA., Gupta SK; Mayo Clinic, Rochester, MN, 55905, USA., Bradshaw GA; Harvard Medical School, Boston, MA, 02115, USA., Hunter AS; Harvard Medical School, Boston, MA, 02115, USA., Carlson BL; Mayo Clinic, Rochester, MN, 55905, USA., Calmo NM; Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA., Chen J; Mayo Clinic, Rochester, MN, 55905, USA.; Shengjing Hospital of China Medical University, Shenyang, 110004, China., Tian S; Mayo Clinic, Rochester, MN, 55905, USA., Sarkaria JN; Mayo Clinic, Rochester, MN, 55905, USA., Nagel ZD; Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA. znagel@hsph.harvard.edu.

Publikováno v: Nature communications [Nat Commun] 2024 Jun 21; Vol. 15 (1), pp. 5294. Date of Electronic Publication: 2024 Jun 21.

Aberrant ATM signaling and homology-directed DNA repair as a vulnerability of p53-mutant GBM to AZD1390-mediated radiosensitization.

Autor: Chen J; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.; Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China., Laverty DJ; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA., Talele S; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55905, USA., Bale A; Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Carlson BL; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Porath KA; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Bakken KK; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Burgenske DM; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Decker PA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA., Vaubel RA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA., Eckel-Passow JE; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA., Bhargava R; Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.; Cancer Center at Illinois, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Lou Z; Division of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA., Hamerlik P; AstraZeneca, Cambridge, UK., Harley B; Department of Chemical and Biomolecular Engineering, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA., Elmquist WF; Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55905, USA., Nagel ZD; Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA 02115, USA., Gupta SK; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA., Sarkaria JN; Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2024 Feb 14; Vol. 16 (734), pp. eadj5962. Date of Electronic Publication: 2024 Feb 14.

Convection enhanced delivery of EGFR targeting antibody-drug conjugates Serclutamab talirine and Depatux-M in glioblastoma patient-derived xenografts.

Autor: Porath KA; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Regan MS; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Griffith JI; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Jain S; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Stopka SA; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Burgenske DM; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Bakken KK; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Carlson BL; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Decker PA; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Vaubel RA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA., Dragojevic S; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Mladek AC; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Connors MA; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Hu Z; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., He L; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Kitange GJ; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Gupta SK; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA., Feldsien TM; Development Sciences, AbbVie Inc., North Chicago, Illinois, USA., Lefebvre DR; Development Sciences, AbbVie Inc., North Chicago, Illinois, USA., Agar NYR; Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Eckel-Passow JE; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA., Reilly EB; Discovery Oncology, AbbVie Inc., North Chicago, Illinois, USA., Elmquist WF; Brain Barriers Research Center, Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota, USA., Sarkaria JN; Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota, USA.

Publikováno v: Neuro-oncology advances [Neurooncol Adv] 2022 Aug 24; Vol. 4 (1), pp. vdac130. Date of Electronic Publication: 2022 Aug 24 (Print Publication: 2022).